Gilteritinib companion diagnostic - Astellas Pharma/ Invivoscribe TechnologiesAlternative Names: ASP 2215 hemifumarate companion diagnostic - Astellas/Invivoscribe; Gilteritinib fumarate companion diagnostic - Astellas/Invivoscribe
Latest Information Update: 16 Feb 2016
At a glance
- Originator Astellas Pharma; Invivoscribe Technologies
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Acute myeloid leukaemia
Most Recent Events
- 28 Apr 2015 Invivoscribe Technologies and Astellas Pharma enter into a collaboration to develop and commercialise a Gilteritinib companion diagnostic